ORIENTBIO Inc.
Financials
Valuation Metrics
ORIENTBIO Inc.'s Market Cap is ₩535B. At end of 2025 it was ₩713B. Ranked #1695 of 2,436 in KR market (top 70%), #677 of 787 on KOSPI (top 86%), #187 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 80%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 53.48B KRW | KR#1,695/2,436 Sec#187/234 |
| Revenue | 29.75B KRW | KR#2,032/2,436 Sec#141/234 |
| Net Income | -4.57B KRW | KR—/2,436 Sec—/234 |
| Total Assets | 81.62B KRW | KR#1,899/2,436 Sec#159/234 |
| Net Assets | 68.54B KRW | KR#1,659/2,436 Sec#143/234 |
| Employees | 106 | KR#1,589/2,436 Sec#123/234 |
| Value | ||
| P/B | 0.78x | KR#1,247/2,436 Sec#72/234 |
| P/S | 1.80x | KR#1,768/2,436 Sec#101/234 |
| FCF Yield | 1.02% | KR#1,139/2,436 Sec#82/234 |
| Profitability | ||
| ROE | -6.66% | KR#1,799/2,436 Sec#136/234 |
| ROA | -5.60% | KR#1,922/2,436 Sec#145/234 |
| Op. Margin | -13.89% | KR#2,057/2,436 Sec#142/234 |
| Revenue Growth | 1.21% | KR#1,358/2,436 Sec#124/234 |
| Financial Health | ||
| Debt Ratio | 119.07% | KR#635/2,436 Sec#80/234 |
| FCF | 547.9M KRW | KR#1,177/2,436 Sec#89/234 |
| Cash | 5.83B KRW | KR#1,928/2,436 Sec#170/234 |
| Current Ratio | 7.82x | KR#158/2,436 Sec#37/234 |
| Performance | ||
| 1Y Return | -32.69% | KR#1,635/2,436 Sec#142/234 |
| 1M Return | 1.35% | KR#749/2,436 Sec#66/234 |
| From 52W High | -44.73% | KR#965/2,436 Sec#76/234 |
| 1Y MDD | -70.16% | KR#1,953/2,436 Sec#167/234 |
| Trading | ||
| Volume | 67,284 shares | KR#1,173/2,436 Sec#114/234 |
| Foreign Own. | 1.01% | KR—/2,436 Sec—/234 |
| Per Share | ||
| EPS | -77 KRW | KR—/2,436 Sec—/234 |
| BPS | 1,156 KRW | KR#2,255/2,436 Sec#202/234 |
Company Info
Established in 1959, the company merged with Biogenomics in 2003 and spun off its watch business in 2005. It operates in laboratory animal production and life science research and development, holding a technical alliance with Charles River Laboratories. The company produces high-quality biological resources using Korea's largest land area and breeding facilities, and also runs a laboratory equipment CRO business. It is dedicated to enhancing technological competitiveness through bio-industry facility construction, advanced equipment development, and clinical trials for new hair loss drugs. Orient Bio is headquartered in Seongnam-si, Gyeonggi.